The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).
Both statins and newer non-statin medications are important in combination to effectively lower atherogenic lipid levels and reduce cardiovascular risk.
Pharmacists can leverage continuous glucose monitoring data to personalize diabetes management, overcome clinical inertia, and improve glycemic control for patients.
The AQUILA study demonstrates that early treatment with daratumumab significantly delays progression to symptomatic multiple myeloma, improves survival outcomes, and offers a well-tolerated alternative to traditional observation.
In hospital and critical care settings, pharmacists can play a significant role in educating other health care providers about treatment options, proper dosing, and more.
Amir Ali, PharmD, BCOP highlights the success of shorter-treatment duration venetoclax in patients with acute myeloid leukemia and efficacy of pre-transplant blinatumomab in those with acute lymphocytic leukemia.
Rakesh Popat, MBBS, PhD explains the mechanisms of action behind the improvement in minimum residual disease in patients with lenalidomide-refractory multiple myeloma with cilta-cel compared with standard of care.
Jason Wang, MD highlights the reduction in incidence and severity of adverse events such as cytokine release syndrome and ICANS following axi-cel treatment in patients with R/R LBCL.
A ketogenic diet and its key metabolite, β-hydroxybutyrate, enhance the efficacy of CAR T-cell therapy by improving metabolic fitness, cytokine production, and cellular expansion, offering a promising, safe strategy for optimizing cancer immunotherapy.
Glucagon-like peptide 1 (GLP1) receptor agonists were shown to be associated with a reduced risk of venous thromboembolism (VTE), while high dietary fiber intake was shown to enhance microbiome health, lower graft-versus-host disease (GVHD) severity, and improve overall survival following allogeneic hematopoietic cell transplantation.
In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.
Donald Moore discusses some of the obstacles that bispecific antibodies have faced in community cancer centers, including misconceptions coupled with a prevalent toxicity profile.
Jose Tinajero discusses how certain mutations can be indicators of blinatumomab treatment failure in patients with B-cell acute lymphoblastic leukemia.
Mazyar Shadman, MD, MPH, discusses the continued efficacy of zanubrutinib in patients with chronic lymphocytic leukemia.
Pelabresib is an investigational, oral, small molecule that inhibits bromodomain and extraterminal (BET) proteins.
The data support the use of supportive anemia care agents in combination with ruxolitinib (Jakafi; Incyte Corp).
The American Society of Hematology (ASH) Annual Meeting and Exposition will include the latest news and clinical trial updates in the hematology field.
Anemia is a very common adverse effect associated with the use of ruxolitinib.
Key trends shaping the future of health-system pharmacy include advanced medication management to address supply chain challenges, digital transformation to enhance pharmacy operations, and strategies for compliance with evolving regulations, all of which will be central topics at the ASHP Midyear 2024 meeting.
AI-powered drug response prediction technology is revolutionizing veterinary and human oncology by enabling personalized treatment plans through live cell testing, machine learning models, and data-driven precision medicine approaches.
Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.
Raymond Lorenz, PharmD, BCPP, discusses the role of pharmacists in bridging laboratory results and clinical practice, highlighting ongoing efforts to establish pharmacogenomic testing standards and foster multidisciplinary collaboration for broader clinical impact.
Jai N. Patel, PharmD, BCOP, CPP, discussed efforts to standardize the evaluation of clinical utility in pharmacogenetics, emphasizing its variability, the role of pharmacogenomics in research, and the importance of robust study designs for pharmacy professionals.
An ACCP speaker explains that the FDA faces a multitude of challenges.
Data show that a child’s insurance status is independently associated with mortality after hematopoietic cell transplantation.
Outpatient models are emerging as feasible alternatives to traditional inpatient care, offering potential benefits such as reduced hospitalization, improved social well-being, and cost savings.
Clinical trial analysis results studying VAD-44 in patients with hereditary hemorrhagic telangiectasia (HTT) will be presented at the 2024 American Society of Hematology Annual Meeting & Exposition.
Christine Formea, PharmD, MHI, BCPS, FCCP, FASHP, discusses the need for standardized pharmacogenomics education in pharmacy, highlighting opportunities for collaboration, professional growth, and integration of key competencies across curricula to advance the profession.
Abelacimab is an investigational, selective, fully human monoclonal antibody.
Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.
